However, in children with PWS, the treatment with a standard GH dose often results in high serum immunoreactive insulin-like growth factor (IGF)-I levels, with levels often being >2 SD score (SDS), which is a concern for clinicians treating children with PWS [5,10,11,12]. This evidence concerns the gene GH1 and Prader-Willi syndrome.